Ventures Fund Iv, L.P.Flags... Net Worth

The estimated Net Worth of Ventures Fund Iv, L.P.Flags... is at least $1.48 Milion dollars as of 6 July 2016. Ventures Flags owns over 400,000 units of Syros Pharmaceuticals stock worth over $1,479,049 and over the last 8 years Ventures sold SYRS stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ventures Flags SYRS stock SEC Form 4 insiders trading

Ventures has made over 1 trades of the Syros Pharmaceuticals stock since 2016, according to the Form 4 filled with the SEC. Most recently Ventures bought 400,000 units of SYRS stock worth $5,000,000 on 6 July 2016.

The largest trade Ventures's ever made was buying 400,000 units of Syros Pharmaceuticals stock on 6 July 2016 worth over $5,000,000. On average, Ventures trades about 200,000 units every 0 days since 2016. As of 6 July 2016 Ventures still owns at least 918,664 units of Syros Pharmaceuticals stock.

You can see the complete history of Ventures Flags stock trades at the bottom of the page.

What's Ventures Flags's mailing address?

Ventures's mailing address filed with the SEC is 55 Cambridge Pkwy, Cambridge, MA 02142, USA.

Insiders trading at Syros Pharmaceuticals

Over the last 8 years, insiders at Syros Pharmaceuticals have traded over $8,259,551 worth of Syros Pharmaceuticals stock and bought 5,052,185 units worth $51,830,966 . The most active insiders traders include Group, Llc Green Jeremy Red..., Srinivas Akkaraju oraz Stephane Bancel. On average, Syros Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $135,148. The most recent stock trade was executed by Richard A Young on 28 June 2024, trading 34,837 units of SYRS stock currently worth $178,365.

What does Syros Pharmaceuticals do?

syros pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical r&d. central to the syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of syros' senior leadership. while this scientific approach has applications in many therapeutic areas, syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.

Complete history of Ventures Flags stock trades at Syros Pharmaceuticals

Syros Pharmaceuticals executives and stock owners

Syros Pharmaceuticals executives and other stock owners filed with the SEC include:

• Nancy Simonian,
  President, Chief Executive Officer, Director
• Joseph Ferra,
  Chief Financial Officer
• Jeremy Springhorn,
  Chief Business Officer
• David Roth,
  Chief Medical Officer
• Eric Olson,
  Chief Scientific Officer
• Gerald Quirk,
  Chief Legal & Administrative Officer
• Dr. Nancy A. Simonian M.D.,
  Pres, CEO & Director
• Dr. David A. Roth,
  Chief Medical Officer
• Dr. Eric R. Olson,
  Chief Scientific Officer
• Richard Young,
  Director
• Dr. Richard A. Young Ph.D.,
  Scientific Founder, Member of Scientific Advisory Board & Director
• Mark Alles,
  Independent Director
• Peter Wirth,
  Independent Chairman of the Board
• Marsha Fanucci,
  Independent Director
• Amir Nashat,
  Independent Director
• Phillip Sharp,
  Independent Director
• Srinivas Akkaraju,
  Independent Director
• Hannah Deresiewicz,
  IR Contact Officer
• S. Gail Eckhardt,
  Director
• Dr. Christian C. Fritz Ph.D.,
  Head of Biology
• Naomi Aoki,
  VP of Corp. Communications & Investor Relations
• Gerald E. Quirk,
  Chief Operations Officer & Sec.
• Jason Haas,
  Chief Financial Officer
• Dr. Nathanael S. Gray Ph.D.,
  Scientific Founder & Member of Scientific Advisory Board
• Dr. James E. Bradner M.D.,
  Founder
• Alice Tsang Shaw,
  Director
• Ventures Fund Iv, L.P.Flags...,
  
• Sanj K Patel,
  Director
• Vicki L Sato,
  Director
• Michael W Bonney,
  Director
• Colleen Elizabeth De Simone,
  Principal Accounting Officer
• Robert Nelsen,
  Director
• Venture Fund Vii, L.P.Arch ...,
  
• Kyle D. Kuvalanka,
  Chief Operating Officer
• Stephane Bancel,
  Director
• Management Co. Vii, L.L.C.P...,
  
• Pharm Tech Healthcare Fund ...,
  10% owner
• Group, Llc Green Jeremy Red...,
  
• Venture Fund Vii Lparch Ven...,
  
• Healthcare Ventures Ii, L.P...,
  10% owner
• James E Deerfield Mgmt L.P....,
  
• Kristin Stephens,
  Chief Development Officer
• Deborah Dunsire,
  
• Jason Haas,
  Chief Financial Officer
• Timothy Tyson,
  
• Conley Chee,
  President & CEO
• Andrew M. Oh,